Announcement on Subsidiary Obtaining Drug Registration Certificate

Zhejiang Sunflower Great Health Co., Ltd.·June 26, 2026·2 pages

✨ AI Summary

Zhejiang Beide Pharmaceutical Co., Ltd., a subsidiary of Zhejiang Sunflower Health Technology Co., Ltd., has received a Drug Registration Certificate for Roxadustat Capsules from the NMPA. This approval, equivalent to a consistency evaluation, is expected to enhance the company's product structure and market competitiveness. The drug is approved for anemia associated with CKD and is already included in China's National Medical Insurance Catalog as a Class B drug.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300111

Securities Abbreviation: Sunflower

Announcement No.: 2026-028

Zhejiang Sunflower Health Technology Co., Ltd.

Announcement on Subsidiary Obtaining Drug Registration Certificate

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.

Zhejiang Sunflower Health Technology Co., Ltd. (hereinafter referred to as the "Company") subsidiary, Zhejiang Beide Pharmaceutical Co., Ltd. (hereinafter referred to as "Beide Pharmaceutical"), recently received the Roxadustat Capsules "Drug Registration Certificate" issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). The relevant situation is as follows:

I. Drug Registration Approval Status

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.